The DEA is suggesting a significant increase to the legal production of psychedelics such as DMT, MDMA, LSD, psilocybin and cannabis, may be for use in research in 2022. In a notice, the Drug Enforcement Administration stated that there had been a considerable increase in the use of Schedule I controlled substances for clinical trial and research purposes, which is why it would like to authorize manufacturers to meet the increasing demand.
The agency had already increased its proposed 2021 quota for psilocybin and marijuana last month. Now, it would like a wider array of psychedelic substances and substantially higher quantities of research-grade cannabis to be manufactured next year. The agency wants to increase the amount of DMT by five times, the amount of mescaline by four times, and double the amount of psilocin, psilocybin and cannabis extracts.
The production amount of DMT will increase by 6,300%, moving from 50g this year to 3,200g in 2022 as research into the therapeutic potential of the drug continues to grow. Cannabis will increase by 60% under the proposal, hitting 3.2 million grams next year while LSD would increase by 1,150%, reaching 500g.
In the Federal Register notice, the DEA stated that it had been approving additional applications to cultivate, extract and manufacture dosage forms that contain particular Schedule I substances for trial purposes in order to meet these quotas. The agency added that it was working hard to process and approve cannabis manufacturer applications especially, because there was only a single farm at the University of Mississippi allowed to grow the plant for research.
The public interest and scientific interest in psychedelic substances and cannabis has grown significantly in the recent past, with initial clinical trials showing the therapeutic potential these substances possess.
In a recent interview, director of the National Institute on Drug Abuse Nora Volkow stated that she was encouraged by the agency’s prior proposed increase in the production quota for the aforementioned substances. She added that the studies showing the therapeutic benefit of psychedelic substances could be leading more individuals to experiment with various psychedelics, including psilocybin.
Despite these increases, experts and advocates remain frustrated that these fungi and plants are still classified under Schedule I in the Controlled Substances Act, even with existing research showing their medical value for various conditions. The Controlled Substances Act was enacted officially in 1971, with substances being classified in different categories. Schedule I substances were considered to be the most dangerous.
The classification is ironic given that plenty of companies, including Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), are in advanced stages of developing medicinal formulations for different indications from these substances, which the DEA classifies as “having no medical value and with a high potential for abuse.”
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
